Taken together, these data support the conclusion that enzalutamide significantly reduces breast cancer cell expression of OPG and this reduced OPG expression leads to a significant increase in tumor cell sensitivity to immune-mediated lysis. This evidence concerns the gene TNFRSF11B and breast carcinoma.